冷冻保存与液态保存血小板治疗手术出血:CLIP-II随机非劣效性临床试验
CLIP-II试验为多中心、随机、双盲、平行组非劣效性研究,于2021年8月至2024年4月在11家澳大利亚三级医院纳入高血小板输注风险的心脏手术患者,排除有深静脉血栓或肺栓塞史、凝血功能障碍、以及18至55岁RhD阴性或RhD状态未知的女性。388例随机,202例接受研究血小板(冷冻保存血小板或常规液态保存血小板,最多3单位,术中或术后24小时内开始输注)。主要终点为ICU入室后24小时胸腔引流量,冷冻保存组605 mL vs 液态保存组535 mL,几何均值比1.13(95%CI 0.96-1.34),P=0.07,因置信区间上限超过20%非劣效界值,非劣效性未成立。冷冻保存血小板组术中及总围术期失血量更高(几何均值比分别为1.42[95%CI 1.12-1.80]和1.31[95%CI 1.07-1.60]),红细胞、血浆和冷沉淀输注增加,拔管时间及ICU/住院时间更长,但预设不良事件发生率无差异。
要点
- 在心脏手术高血小板输注风险患者中,冷冻保存血小板组ICU入室后24小时胸腔引流量605 mL vs 液态保存组535 mL,几何均值比1.13(95%CI 0.96-1.34),非劣效性未成立。
- 冷冻保存血小板组术中失血量几何均值比为液态保存组的1.42倍(95%CI 1.12-1.80),总围术期失血量为1.31倍(95%CI 1.07-1.60)。
- 冷冻保存血小板组红细胞、血浆和冷沉淀输注均增加。
- 冷冻保存血小板组拔管时间、ICU停留时间和住院时间均长于液态保存组:机械通气25.5小时 vs 23.6小时,ICU停留3.8天 vs 3.0天,住院10.9天 vs 9.1天。
- 两组预设不良事件发生率无差异。
适用人群与场景
- 心脏手术且高血小板输注风险的患者,于2021年8月至2024年4月在11家澳大利亚三级医院纳入。
- 排除有深静脉血栓或肺栓塞史、凝血功能障碍、以及18至55岁RhD阴性或RhD状态未知的女性。
处置流程与药物剂量
- 术中或术后24小时内开始输注最多3单位O型冷冻保存血小板或常规液态保存血小板。
研究设计与关键结果
- 多中心、随机、双盲、平行组非劣效性试验,388例随机,202例接受研究血小板(平均[SD]年龄64.4[13]岁,75.7%男性,30.2%接受非择期手术)。
- 主要终点ICU入室后24小时胸腔引流量:冷冻保存血小板组605 mL vs 液态保存血小板组535 mL,几何均值比1.13(95%CI 0.96-1.34),P=0.07;置信区间上限超过预设20%非劣效界值,非劣效性未成立。
- 术中失血量几何均值比(冷冻保存/液态)1.42(95%CI 1.12-1.80),总围术期失血量几何均值比1.31(95%CI 1.07-1.60),冷冻保存组更高。
- 冷冻保存血小板组红细胞、血浆和冷沉淀输注增加。
- 预设不良事件发生率无差异;冷冻保存组拔管时间、ICU停留时间和住院时间更长:机械通气中位25.5小时(IQR 16.1-77.3)vs 23.6小时(IQR 13.1-52.8),ICU停留中位3.8天(IQR 2.0-6.0)vs 3.0天(IQR 1.9-4.9),住院中位10.9天(IQR 7.87-17.0)vs 9.1天(IQR 6.9-14.9)。
证据类型、等级与局限
- 证据类型:多中心、随机、双盲、平行组非劣效性临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,冷冻保存血小板在ICU入室后24小时止血效果未达到预设非劣效界值,多个预设终点一致提示止血效果减弱,尽管预设不良事件相当。
指南或共识出处
- CLIP-II试验(ClinicalTrials.gov Identifier: NCT03991481)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Liquid-stored platelets have a shelf-life of 5 to 7 days, limiting availability and resulting in wastage.
OBJECTIVE: To assess the effectiveness and safety of dimethyl sulfoxide-cryopreserved platelets, which have a shelf-life of 2 years, as a treatment for cardiac surgery bleeding.
DESIGN, SETTING, AND PARTICIPANTS: The Cryopreserved vs Liquid Platelets II (CLIP-II) trial was a multicenter, randomized, double-blind, parallel-group noninferiority trial, which enrolled patients between August 2021 and April 2024 at 11 Australian tertiary hospitals, with follow-up completed in July 2024. Patients at high risk of platelet transfusion were eligible. Patients were excluded if they had a history of deep vein thrombosis or pulmonary embolism, were coagulopathic, or were females aged 18 to 55 years who were rhesus D (RhD) negative or of unknown RhD status. Of 879 patients meeting inclusion criteria, 182 were excluded and 285 did not consent, leaving 412. Of these, 388 were randomized and 202 received study platelets.
INTERVENTIONS: Patients received up to 3 units of either group O cryopreserved platelets or conventional liquid-stored platelets, commencing intraoperatively or in the first 24 postoperative hours.
MAIN OUTCOMES AND MEASURES: The primary outcome was postsurgical chest drain bleeding within the first 24 hours following intensive care unit admission. Noninferiority was defined prospectively as less than 20% greater bleeding in this period. Five secondary and 42 tertiary outcomes were defined a priori.
RESULTS: Of the 202 transfused patients (mean [SD] age, 64.4 [13] years; 75.7% male), 61 (30.2%) underwent nonelective surgery. The primary outcome did not differ between groups (605 mL in cryopreserved platelet group vs 535 mL in liquid-stored platelet group; ratio of geometric means [cryopreserved to liquid ratio], 1.13 [95% CI, 0.96-1.34]; P = .07). As the confidence interval includes bleeding exceeding the noninferiority margin, noninferiority was not established. Cryopreserved platelet transfusion was associated with higher intraoperative and total perioperative blood loss (ratio of geometric means [cryopreserved to liquid ratio], 1.42 [95% CI, 1.12-1.80]; 1.31 [95% CI, 1.07-1.60], respectively), and increased red cell, plasma, and cryoprecipitate transfusion. While there were no differences in the incidence of prespecified adverse events, patients receiving cryopreserved platelets experienced longer times to extubation and intensive care unit/hospital discharge (median [IQR] duration of ventilation, 25.5 hours [16.1-77.3] vs 23.6 hours [13.1-52.8]; median [IQR] intensive care unit length of stay, 3.8 days [2.0-6.0] vs 3.0 days [1.9-4.9]; median hospital length of stay, 10.9 days [7.87-17.0] vs 9.1 [6.9-14.9]).
CONCLUSIONS AND RELEVANCE: Cryopreserved platelets did not meet the predefined threshold for noninferiority in hemostatic effectiveness at 24 hours after ICU admission. Additional predefined end points consistently indicated diminished hemostatic effectiveness, although prespecified adverse events were comparable.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03991481.
参考来源
- Reade MC, Marks DC, Howe BD, et al. Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial. JAMA. 2026. PMID: 41360717. doi:10.1001/jama.2025.23355
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。